LinkedIn Profile

Access Oncobox historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:oncobox 18043403 Mar 18th, 2023 12:00AM Oncobox 117 4.00 Open Medical Equipment Manufacturing Mar 18th, 2023 08:58PM Mar 18th, 2023 08:58PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 17th, 2023 12:00AM Oncobox 117 4.00 Open Medical Equipment Manufacturing Mar 17th, 2023 03:07PM Mar 17th, 2023 03:07PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 16th, 2023 12:00AM Oncobox 117 5.00 Open Medical Equipment Manufacturing Mar 16th, 2023 08:05PM Mar 16th, 2023 08:05PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 15th, 2023 12:00AM Oncobox 117 5.00 Open Medical Equipment Manufacturing Mar 15th, 2023 04:57PM Mar 15th, 2023 04:57PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 14th, 2023 12:00AM Oncobox 117 5.00 Open Medical Equipment Manufacturing Mar 14th, 2023 05:24PM Mar 14th, 2023 05:24PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 13th, 2023 12:00AM Oncobox 117 5.00 Open Medical Equipment Manufacturing Mar 13th, 2023 07:41PM Mar 13th, 2023 07:41PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 12th, 2023 12:00AM Oncobox 117 5.00 Open Medical Equipment Manufacturing Mar 12th, 2023 05:29PM Mar 12th, 2023 05:29PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 11th, 2023 12:00AM Oncobox 117 5.00 Open Medical Equipment Manufacturing Mar 11th, 2023 07:17PM Mar 11th, 2023 07:17PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 10th, 2023 12:00AM Oncobox 117 5.00 Open Medical Equipment Manufacturing Mar 11th, 2023 06:42AM Mar 11th, 2023 06:42AM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox
private:oncobox 18043403 Mar 9th, 2023 12:00AM Oncobox 117 5.00 Open Medical Equipment Manufacturing Mar 9th, 2023 07:41PM Mar 9th, 2023 07:41PM Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would be most effective in fighting individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe on 250+ prospective patients with a variety of late-stage cancers, Oncobox increased the effectiveness of targeted therapies from up to 70%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock, they don’t always know which drug will be most effective for their patients, and because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Integral Test analyzes DNA and RNA of over 8,000 genes that are included in major molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases and finds the right drug for them. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We are actively seeking partners from pharma, hospitals/clinicians, payers, and genomic centers. If you are in Oncobox for your patients, contact us at hello@oncobox.com. Our team and scientific advisory board consists of leading scientists and researchers from Stanford, Caltech, University of Mainz, Boston University, Moscow State University, Tufts University, and Rutgers University. Open biomedicine, cancer, diagnostics, and bioinformatics Open 340 S Lemon Ave Walnut California US 91789 Oncobox

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.